These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35113275)

  • 21. Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.
    Desai RJ; Varma VR; Gerhard T; Segal J; Mahesri M; Chin K; Horton DB; Kim SC; Schneeweiss S; Thambisetty M
    JAMA Netw Open; 2022 Apr; 5(4):e226567. PubMed ID: 35394510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
    Cheng D; Kochar B; Cai T; Ritchie CS; Ananthakrishnan AN
    Am J Gastroenterol; 2022 Nov; 117(11):1845-1850. PubMed ID: 35854436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory bowel disease and venous thromboembolism during pregnancy and the postpartum period.
    Hansen AT; Erichsen R; Horváth-Puhó E; Sørensen HT
    J Thromb Haemost; 2017 Apr; 15(4):702-708. PubMed ID: 28135041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical presentation of venous thromboembolism in inflammatory bowel disease.
    Papay P; Miehsler W; Tilg H; Petritsch W; Reinisch W; Mayer A; Haas T; Kaser A; Feichtenschlager T; Fuchssteiner H; Knoflach P; Vogelsang H; Platzer R; Tillinger W; Jaritz B; Schmid A; Blaha B; Dejaco C; Sobala A; Weltermann A; Eichinger S; Novacek G
    J Crohns Colitis; 2013 Oct; 7(9):723-9. PubMed ID: 23127785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
    Thomsen SB; Ungaro RC; Allin KH; Elmahdi R; Poulsen G; Andersson M; Colombel JF; Jess T
    Aliment Pharmacol Ther; 2022 May; 55(9):1128-1138. PubMed ID: 35080036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and Risk Factor Analysis of Thromboembolic Events in East Asian Patients With Inflammatory Bowel Disease, a Multinational Collaborative Study.
    Weng MT; Park SH; Matsuoka K; Tung CC; Lee JY; Chang CH; Yang SK; Watanabe M; Wong JM; Wei SC
    Inflamm Bowel Dis; 2018 Jul; 24(8):1791-1800. PubMed ID: 29726897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
    Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases.
    Ananthakrishnan AN; Cagan A; Gainer VS; Cheng SC; Cai T; Scoville E; Konijeti GG; Szolovits P; Shaw SY; Churchill S; Karlson EW; Murphy SN; Kohane I; Liao KP
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1905-10. PubMed ID: 24632349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease.
    Andersson P; Karling P
    Ups J Med Sci; 2022; 127():. PubMed ID: 35140875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Venous and arterial thromboembolism in patients with inflammatory bowel diseases.
    Stadnicki A; Stadnicka I
    World J Gastroenterol; 2021 Oct; 27(40):6757-6774. PubMed ID: 34790006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.
    Lewis JD; Scott FI; Brensinger CM; Roy JA; Osterman MT; Mamtani R; Bewtra M; Chen L; Yun H; Xie F; Curtis JR
    Am J Gastroenterol; 2018 Mar; 113(3):405-417. PubMed ID: 29336432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk Factors for Venous Thromboembolism in Children and Young Adults With Inflammatory Bowel Disease.
    McKie K; McLoughlin RJ; Hirsh MP; Cleary MA; Aidlen JT
    J Surg Res; 2019 Nov; 243():173-179. PubMed ID: 31181463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study.
    Kappelman MD; Horvath-Puho E; Sandler RS; Rubin DT; Ullman TA; Pedersen L; Baron JA; Sørensen HT
    Gut; 2011 Jul; 60(7):937-43. PubMed ID: 21339206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease.
    Dolovich C; Bernstein CN; Singh H; Nugent Z; Tennakoon A; Shafer LA; Marrie RA; Sareen J; Targownik LE
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1200-1208.e1. PubMed ID: 32668341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF.
    Cachen L; Nocturne G; Collins M; Meyer A; Gleizes A; Hacein-Bey-Abina S; Carbonnel F; Mariette X; Seror R
    RMD Open; 2022 Jan; 8(1):. PubMed ID: 35091460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases.
    Dheyriat L; Ward D; Beaugerie L; Jess T; Kirchgesner J
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):164-172.e11. PubMed ID: 35842123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.